This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Japan IP Court upholds revocation of Boehringer's diabetes drug-dosage patent

By Toko Sekiguchi ( February 17, 2026, 08:02 GMT | Insight) -- Japan’s Intellectual Property High Court upheld the invalidation of Boehringer Ingelheim’s patent for its diabetes drug, finding that the claimed regimen was a routine refinement within known ranges rather than a genuine technical breakthrough.Japan’s Intellectual Property High Court upheld the invalidation of Boehringer Ingelheim’s patent for its diabetes drug, finding that the claimed regimen was a routine refinement within known ranges rather than a genuine technical breakthrough....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections